RPh RPh - Amneal Pharmaceuticals, CoCEO CoFounder

AMRX Stock  USD 7.82  0.10  1.26%   

Insider

RPh RPh is CoCEO CoFounder of Amneal Pharmaceuticals, Class
Age 52
Address 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807
Phone908 947 3120
Webhttps://amneal.com

Amneal Pharmaceuticals, Management Efficiency

The company has return on total asset (ROA) of 0.0594 % which means that it generated a profit of $0.0594 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8577) %, meaning that it created substantial loss on money invested by shareholders. Amneal Pharmaceuticals,'s management efficiency ratios could be used to measure how well Amneal Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.12 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.04). At this time, Amneal Pharmaceuticals,'s Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 933.3 M in 2024, whereas Total Assets are likely to drop slightly above 3.2 B in 2024.
Amneal Pharmaceuticals, Class currently holds 2.75 B in liabilities. Amneal Pharmaceuticals, has a current ratio of 1.71, which is within standard range for the sector. Note, when we think about Amneal Pharmaceuticals,'s use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Damian FinioPhibro Animal Health
54
Floyd MDAlkermes Plc
87
Muthusamy RPhANI Pharmaceuticals
56
Elizabeth JDANI Pharmaceuticals
N/A
Jean FilippiPhibro Animal Health
N/A
John MinardoIronwood Pharmaceuticals
48
Albert BollesLifecore Biomedical
66
Beth CalitriIronwood Pharmaceuticals
N/A
Marlo ManningCollegium Pharmaceutical
N/A
Eiry MDNeurocrine Biosciences
60
Sandra BeaverEvolus Inc
46
Ziping LuoAmphastar P
74
Jason RickardIronwood Pharmaceuticals
53
CCFP DipSportMedEvolus Inc
60
CPA CPAIntracellular Th
68
Daniel PeisertAssertio Therapeutics
49
Nicole ArndtDynavax Technologies
N/A
Ajay PatelAssertio Therapeutics
40
Jacob MBAAmphastar P
50
Aaron PerlitshLifecore Biomedical
N/A
Melissa AngeliniProcaps Group SA
N/A
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. Amneal Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 7000 people. Amneal Pharmaceuticals, Class (AMRX) is traded on New York Stock Exchange in USA and employs 7,850 people. Amneal Pharmaceuticals, is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Amneal Pharmaceuticals, Leadership Team

Elected by the shareholders, the Amneal Pharmaceuticals,'s board of directors comprises two types of representatives: Amneal Pharmaceuticals, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amneal. The board's role is to monitor Amneal Pharmaceuticals,'s management team and ensure that shareholders' interests are well served. Amneal Pharmaceuticals,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amneal Pharmaceuticals,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
Sanjay Jain, President Operations
Anastasios Konidaris, Chief Financial Officer, Executive Vice President
John Kiely, Independent Director
Gautam Patel, Director
Pranav Mehta, Senior Management
Nikita Shah, Chief Human Resource Officer, Executive Vice President, Strategic Planning Officer
Paul Meister, Independent Chairman of the Board
Jason Esq, Chief VP
Andrew Boyer, Executive Vice President, Chief Commercial Officer - Generics
Ted Nark, Independent Director
Jeffrey George, Independent Director
Shlomo Yanai, Independent Director
Nikunj Patel, Head Ltd
Gregory Sgammato, Senior Development
Chintu Patel, Co-Chief Executive Officer, Co-Founder, Director
Stephen Manzano, Senior Vice President, General Counsel and Corporate Secretary
Sanjiv Patel, VP Operations
Emily Alva, Independent Director
Anthony DiMeo, Director Relations
Joseph Greer, Senior Vice President - Global Quality Management
Jason Daly, Senior Vice President Chief Legal Officer and Corporate Secretary
Apurva Saraf, Senior Vice President - Corporate Development
Chintu RPh, CoCEO CoFounder
RPh RPh, CoCEO CoFounder
J Buchi, Independent Director
Chirag Patel, President, Co-Chief Executive Officer, Co-Founder, Director
Joseph Todisco, Executive Vice President, Chief Commercial Officer - Specialty

Amneal Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amneal Pharmaceuticals, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.